Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus

Journal of General Virology

Volumn 89, Issue 4, 2008, Pages 939-948

  Gabriel, Gülsah ^a,c   Nordmann, Alexandra ^a   Stein, David A ^b   Iversen, Patrick L ^b   Klenk, Hans Dieter ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b AVI BIOPHARMA INC   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; MESSENGER RNA; OLIGOMER; PEPTIDE CONJUGATED PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; POLYMERASE BASIC PROTEIN 1; VIRUS NUCLEOPROTEIN; VIRUS RNA; ANTIINFECTIVE AGENT; CORE PROTEIN; INFLUENZA VIRUS POLYMERASE BASIC PROTEIN 1; MORPHOLINE DERIVATIVE; NP PROTEIN, INFLUENZA A VIRUS; NUCLEOPROTEIN; PEPTIDE; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; RNA BINDING PROTEIN; VIRUS PROTEIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY TEST; FEMALE; GENE TARGETING; INFLUENZA; INFLUENZA VIRUS A H7N7; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA ANALYSIS; RNA SEQUENCE; SURVIVAL RATE; TERMINAL SEQUENCE; TRANSLATION INITIATION; VIROGENESIS; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DOG; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG SCREENING; GENETICS; INFLUENZA VIRUS A; INTRANASAL DRUG ADMINISTRATION; ORTHOMYXOVIRUS INFECTION; SYNTHESIS; VIRUS GENE;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-INFECTIVE AGENTS; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; GENE TARGETING; GENES, VIRAL; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H7N7 SUBTYPE; MICE; MICE, INBRED BALB C; MORPHOLINES; NUCLEOPROTEINS; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDES; RNA-BINDING PROTEINS; VIRAL CORE PROTEINS; VIRAL PROTEINS;

EID: 45549109283     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.83449-0     Document Type: Article

References (44)

1. Abe, T., Mizuta, T., Hatta, T., Miyano-Kurosaki, N., Fujiwara, M., Takai, K., Shigeta, S., Yokota, T. & Takaku, H. (2001). Antisense therapy of influenza. Eur J Pharm Sci 13, 61-69.
2. Abes, S., Moulton, H. M., Clair, P., Prevot, P., Youngblood, D. S., Wu, R. P., Iversen, P. L. & Lebleu, B. (2006). Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 116, 304-313.
3. Brown, M. A. & Hural, J. (1997). Functions of IL-4 and control of its expression. Crit Rev Immunol 17, 1-32.
4. Burrer, R., Neuman, B. W., Ting, J. P., Stein, D. A., Moulton, H. M., Iversen, P. L., Kuhn, P. & Buchmeier, M. J. (2007). Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J Virol 81, 5637-5648.
5. Claas, E. C., Osterhaus, A. D., van Beek, R., De Jong, J. C., Rimmelzwaan, G. F., Senne, D. A., Krauss, S., Shortridge, K. F. & Webster, R. G. (1998). Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351, 472-477.
6. de Jong, M. D., Tran, T. T., Truong, H. K., Vo, M. H., Smith, G. J., Nguyen, V. C., Bach, V. C., Phan, T. O., Do, O. H. & other authors (2005). Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353, 2667-2672.
7. de Jong, M. D., Simmons, C. P., Thanh, T. T., Hien, V. M., Smith, G. J., Chau, T. N., Hoang, D. M., Chau, N. V., Khanh, T. H. & other authors (2006). Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12, 1203-1207.
8. Deas, T. S., Bennett, C. J., Jones, S. A., Tilgner, M., Ren, P., Behr, M. J., Stein, D. A., Iversen, P. L., Kramer, L. D. & other authors (2007). In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob Agents Chemother 51, 2470-2482.
9. Elton, D., Digard, P., Tiley, L. & Orlin, J. (2006). Structure and Function of Influenza Virus RNP. Influenza Virology: Current Topics, chapter 1, pp. 1-36. Edited by Y. Kawaoka. Horizon Scientific Press.
10. Enterlein, S., Warfield, K. L., Swenson, D. L., Stein, D. A., Smith, J. L., Gamble, C. S., Kroeker, A. D., Iversen, P. L., Bavari, S. & Muhlberger, E. (2006). VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 50, 984-993.
11. Flick R., Neumann, G., Hoffmann, E., Neumeier, E. & Hobom, G. (19916). Promoter elements in the influenza vRNA terminal structure. RNA 2, 1046-1057.
12. Fodor, E. & Smith, M. (2004). The PA subunit is required for efficient nuclear accumulation of the PB1 subunit of the influenza A virus RNA polymerase complex. J Virol 78, 9144-9153.
13. Fodor, E., Crow, M., Mingay, L. J., Deng, T., Sharps, J., Fechter, P. & Brownlee, G. G. (2002). A single amino acid mutation in the PA subunit of the influenza virus RNA polymerase inhibits endonucleolytic cleavage of capped RNAs. J Virol 76, 8989-9001.
14. Fouchier, R. A., Schneeberger, P. M., Rozendaal, F. W., Broekman, J. M., Kemink, S. A., Munster, V., Kuiken, T., Rimmelzwaan, G. F., Schutten, M. & other authors (2004). Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 101, 1356-1361.
15. Gabriel, G., Dauber, B., Wolff, T., Planz, O., Klenk, H. D. & Stech, J. (2005). The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl Acad Sci U S A 102, 18590-18595.
16. Gabriel, G., Abram, M., Keiner, B., Wagner, R., Klenk, H. D. & Stech, J. (2007). Differential polymerase activity in avian and mammalian cells determines host range of influenza virus. J Virol 81, 9601-9604.
17. Ge, O., McManus, M. T., Nguyen, T., Shen, C. H., Sharp, P. A., Eisen, H. N. & Chen, J. (2003). RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci U S A 100, 2718-2723.
18. Ge, O., Eisen, H. N. & Chen, J. (2004a). Use of siRNAs to prevent and treat influenza virus infection. Virus Res 102, 37-42.
19. Ge, O., Filip, L., Bai, A., Nguyen, T., Eisen, H. N. & Chen, J. (2004b). Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 101, 8676-8681.
20. Ge, O., Pastey, M., Kobasa, D., Puthavathana, P., Lupfer, C., Bestwick, R. K., Iversen, P. L., Chen, J. & Stein, D. A. (2006). Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers. Antimicrob Agents Chemother 50, 3724-3733.
21. Hofmann, S. R., Ettinger, R., Zhou, Y. J., Gadina, M., Lipsky, P., Siegel, R., Candotti, F. & O'Shea, J. J. (2002). Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol 2, 495-506.
22. Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N. & Kawaoka, Y. (2004). Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364, 759-765.
23. Kobasa, D., Jones, S. M., Shinya, K., Kash, J. C., Copps, J., Ebihara, H., Hatta, Y., Kim, J. H., Halfmann, P. & other authors (2007). Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445, 319-323.
24. Le, O. M., Kiso, M., Someya, K., Sakai, Y. T., Nguyen, T. H., Nguyen, K. H., Pham, N. D., Ngyen, H. H., Yamada, S. & other authors (2005). Avian flu: isolation of drug-resistant H5N1 virus. Nature 437, 1108.
25. Li, S. O., Orlich, M. & Rott, R. (1990). Generation of seal influenza virus variants pathogenic for chickens, because of hemagglutinin cleavage site changes. J Virol 64, 3297-3303.
26. Ludwig, S., Planz, O., Pleschka, S. & Wolff, T. (2003). Influenza-virus-induced signaling cascades: targets for antiviral therapy? Trends Mol Med 9, 46-52.
27. McKimm-Breschkin, J. L. (2000). Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res 47, 1-17.
28. Monteiro, J. M., Harvey, C. & Trinchieri, G. (1998). Role of interleukin-12 in primary influenza virus infection. J Virol 72, 4825-4831.
29. Moulton, H. M., Nelson, M. H., Hatlevig, S. A., Reddy, M. T. & Iversen, P. L. (2004). Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 15, 290-299.
30. Neumann, G., Brownlee, G. G., Fodor, E. & Kawaoka, Y. (2004). Orthomyxovirus replication, transcription, and polyadenylation. Curr Top Microbiol Immunol 283, 121-143.
31. Plehn-Dujowich, D. & Altman, S. (1998). Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P. Proc Natl Acad Sci U S A 95, 7327-7332.
32. Scheiblauer, H., Kendal, A. P. & Rott, R. (1995). Pathogenicity of influenza A/Seal/Mass/1/80 virus mutants for mammalian species. Arch Virol 140, 341-348.
33. Stein, D., Foster, E., Huang, S. B., Weller, D. & Summerton, J. (1997). A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 7, 151-157.
34. Subbarao, K., Klimov, A., Katz, J., Regnery, H., Lim, W., Hall, H., Perdue, M., Swayne, D., Bender, C. & other authors (1998). Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279, 393-396.
35. Summerton, J. (1999). Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1489, 141-158.
36. Summerton, J. & Weller, D. (1997). Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7, 187-195.
37. Tado. M., Abe, T., Hatta, T., Ishikawa, M., Niakada, S., Yokota, T. & Takaku, H. (2001). Inhibitory effect of modified 5'-capped short RNA fragments on influenza virus RNA polymerase gene expression. Antir Chem Chemother 12, 353-358.
38. Takahashi, H., Hamazaki, H., Habu, Y., Hayashi, M., Abe, T., Miyano-Kurosaki, N. & Takaku, H. (2004). A new modified DNA enzyme that targets influenza virus A mRNA inhibits viral infection in cultured cells. FEBS Lett 560, 69-74.
39. Tompkins, S. M., Lo, C. Y., Tumpey, T. M. & Epstein, S. L. (2004). Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A 101, 8682-8686.
40. Tumpey, T. M., Lu, X., Morken, T., Zaki, S. R. & Katz, J. M. (2000). Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol 74, 6105-6116.
41. Verbeek, W., Faulhaber, M., Griesinger, F. & Britinger, G. (2000). Measueement of thrombopoietic levels: clinical and biological relationships. Curr Opin Hematol 7, 143-149.
42. Winsor, G. L., Waterhouse, C. C., MacLellan, R. L. & Stadnyk, A. W. (2000). Interleukin-4 and IFN-gamma differentially stimulate macrophage chemoattractant protein-1 (MCP-1) and cotaxin production by intestinal epithelial cells. J Interferon Cytokine Res 20, 299-308.
43. Wolber, E. M. & Jelkmann, W. (2002). Thrombopoietin: the novel hepatic hormone. News Physiol Sci 17, 6-10.
44. Yuan, J., Stein, D. A., Lim, T., Olu, D., Coughlin, S., Liu, Z., Wang, Y., Blouch, R., Moulton, H. M. & other authors (2006). Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J Virol 80, 11510-11519.